Ovarian Cancer Clinical Trials in Fort Worth, Texas

8 studies are recruiting for ovarian cancer in Fort Worth, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

   The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Jps Health Network, Fort Worth, Texas

   Locations

   192 in total

   Run by

   Incyte Corporation

   See if you can join NCT07214779 on ClinicalTrials.gov

2. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

   The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjuga…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Start Dfw, Fort Worth, Texas

   Locations

   29 in total

   Run by

   Tubulis GmbH

   See if you can join NCT06303505 on ClinicalTrials.gov

3. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Start - Dfw, Fort Worth, Texas

   Locations

   26 in total

   Run by

   SystImmune Inc.

   See if you can join NCT06293898 on ClinicalTrials.gov

4. A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

   The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Texas Oncology - DFW ( Site 8001), Fort Worth, Texas

   Locations

   196 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06824467 on ClinicalTrials.gov

5. A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

   Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in part…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Texas Oncology - Fort Worth Cancer Center /ID# 277989, Fort Worth, Texas

   Locations

   83 in total

   Run by

   AbbVie

   See if you can join NCT07059845 on ClinicalTrials.gov

6. Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors

   The primary purpose of this study is to determine whether the combination of the investigational drug XmAb541 in combination with the investigational drug XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of X…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Xencor Investigative Site, Fort Worth, Texas

   Locations

   4 in total

   Run by

   Xencor, Inc.

   See if you can join NCT07593092 on ClinicalTrials.gov

7. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Center for Cancer Research - Texas, Fort Worth, Texas

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

8. Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

   The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Dallas, Fort Worth, Texas

   Locations

   3 in total

   Run by

   Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

   See if you can join NCT07517198 on ClinicalTrials.gov